Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study
Frontiers in Pharmacology · 02.06.2025 · 16
DOI: 10.3389/fphar.2025.1523339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.06.2025. Verfasst von Fangfang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Third Hospital, Beijing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Etrasimod is an investigational, oral, once-daily, selective S1P 1,4,5 receptor modulator in development for the treatment of immune-mediated inflammatory diseases. We present safety, tolerability, pharmacokinetic, and pharmacodynamic results of etrasimod treatment in healthy Chinese adults.
Methods
In a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study, healthy Chinese adult subjects were randomly assigned to 3 cohorts. Cohorts 1 and 2 were given single-dose etrasimod, 1 mg or 2 mg, respectively, or placebo, followed by washout, then multiple-dose periods. Cohort 3 received multiple-dose etrasimod 2 mg or placebo, followed by titration to 3 mg or placebo. Cardiac monitoring included 24-h dynamic electrocardiogram, electrocardiogram monitoring, and 12-lead electrocardiogram. The primary endpoints were safety and tolerability, and secondary endpoints were pharmacokinetic and pharmacodynamic responses to etrasimod.
Results
All treatment-emergent adverse events were Common Terminology Criteria for Adverse Events Grade 1 in severity, and all events were resolved without medical intervention. The most frequent event was sinus bradycardia (heart rate <50 bpm), and all these events were asymptomatic. No infections or infection-related events were reported. Pharmacokinetic and pharmacodynamic responses to etrasimod were consistent with previous studies in other populations. Etrasimod exposure increased at least dose proportionally for multiple doses and exhibited a half-life between 28.1 and 37.9 h. Etrasimod dose-dependently reduced lymphocyte counts, and these reductions were primarily seen in T naïve, T central memory, and T helper cells.
Conclusion
Etrasimod was safe and well-tolerated in healthy Chinese subjects up to 3 mg in single and multiple-dose periods. Clinical Trial Registration http://www.chinadrugtrials.org.cn , identifier: CTR20190003.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University Third Hospital, Beijing, China.
- Everest Medicines, Shanghai, China.
Zitieren
APA
Wang, F., Niu, X., Liu, N., Zhu, Z., Lin, Y., Ying, L., & Li, H. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1523339
Vancouver
Wang F, Niu X, Liu N, Zhu Z, Lin Y, Ying L, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1523339
BibTeX
@article{Wang2025,
author = {Wang, Fangfang and Niu, Xiaoye and Liu, Na and Zhu, Zhengying and Lin, Yun and Ying, Lisa and Li, Haiyan},
title = {Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1523339}
}
EUVIMED